Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
765IGF-MTX in Advanced MDS, CMML, and Oligoblastic AML
NCT03175978Phase 2Terminated
- Sponsor
- IGF Oncology
- Start
- Feb 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 765IGF-MTX in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by IGF Oncology. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events up to 10 months. Started Feb 2018; status: terminated.
02
Drugs
765IGF-MTX
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03175978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175978.